• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

BioMarin, having retrenched, outlines plans for growth

cafead

Administrator
Staff member
  • cafead   Sep 04, 2024 at 11:02: PM
via On Wednesday, executives unveiled their long-term plans for growth at an anticipated investor day, outlining guidance for revenue and new drug approvals over the next decade. They also debuted a new company structure that splits its business into three separate segments.

article source
 

<